Age-standardized pancreatic cancer mortality rates have not improved since 2010-2014.
-
EU 2021 cancer mortality trends differ between men and women -
Do beta-blockers boost survival in lung cancer? Meta-analysis finds OS benefit in stage III disease and non-surgical patients.
-
ES-SCLC: trilaciclib approved for benefit against chemotherapy-induced myelosuppression First and only drug approved for patients receiving platinum/etoposide or topotecan chemotherapy.
-
WCLC 2020 — Pretreated NSCLC: KRAS inhibitor sotorasib shines in phase 2 trial Authors call findings an historic milestone.
-
WCLC 2020 — NSCLC: pembrolizumab-ipilimumab combo fails phase 3 trial Survival and response did not improve vs pembrolizumab alone.
-
WCLC 2020 — NSCLC: long-term survival after second-line immunotherapy is remarkable 5-year follow-up data from pembrolizumab and nivolumab trials.
-
WCLC 2020 — NSCLC: no survival boost with chemotherapy based on mRNA expression Results from the ITACA study.
-
NSCLC: does performance status diminish pembrolizumab efficacy? Study finds that patients with ECOG PS ≥2 fare significantly worse.
-
WCLC 2020 — For NSCLC, neoadjuvant atezolizumab is safe and yields good response The complete resection rate was comparable to the rate in a preoperative chemotherapy trial.
-
WCLC 2020 — In EGFR-mutated NSCLC, amivantamab shows phase 1 promise Results from the CHRYSALIS study.
-
Should chest X-ray be the first test for lung cancer? UK study finds that current guidelines recommending X-ray first lead to a delayed diagnosis.
-
An open-label, single-arm, phase 2a clinical trial from the MiST1 study group.
-
The study shows that the fossil fuel component of PM2.5 contributes a large global mortality burden, and supports switching to renewable energy.
-
WCLC 2020 — Relapsed mesothelioma: nivolumab boosts survival Findings from the phase 3 CONFIRM trial.